General Session VI: Experimental Therapeutics A: EGFR
Track
:
General Session
Program Code:
090
Date:
Thursday, November 13, 2008
Time:
4:15 PM to 5:15 PM
EST
Duration:
3290 Minutes
Location:
Grand Ballroom 1/II
SPEAKER(S):
Click the plus sign to see more detailed information
about each speaker.
Ramaswamy Govindan, M.D., Associate Professor of Medicine, Washington University
I direct the thoracic oncology program at Washington University School of Medicine. My specific research interests include prediction of biomarkers for recurrence, developing novel therapies and using novel imaging modalities to predict response to therapy
Fred Hirsch, M.D., Ph.D., University of Colorado Cancer Center, Aurora, Colo.
Professor of Medicine and Pathology, University of Colorado
Pasi Janne, M.D., Ph.D., Medical Oncologist, Dana-Farber Cancer Institute
Dr. Jänne has made significant contribitions to understanding resistance mechanisms to EGFR targetes therapies in lung cancer.
Determine the patient population that could be most appropriate for whole brain irradiation and radiosurgery
Explain the neurocognitive advantage and disadvantage of whole brain irradiation and stereotactic radiosurgery